|
| Trial | Inclusion | Exclusion | Dosage | IVB location | Laser photocoagulation during follow-up | Surgeon |
|
| Salehi et al. [11] | (1) CSME; (2) mild, moderate, severe, or very severe NPDR or PDR; or (3) a combination of 1 and 2. Patients with previous focal or grid laser photocoagulation for CSME were eligible | Those with previous PRP for PDR | IVB: 1.25 mg | 3.5 mm posterior to the inferotemporal limbus using a 27-gauge needle | Laser photocoagulation was performed according to ETDRS guidelines | One |
| Fard et al. [12] | Moderate or severe NPDR, preoperative visual acuity ≤20/50, preoperative central MT < 200 μm | Prior laser photocoagulation in the study eye | IVB: 1.25 mg | 3.5 mm posterior to limbus with a 30-gauge needle | PRP was performed according to ETDRS guidelines for DR | One |
| Takamura et al. [13] | NPDR with DME (MT > 300 μm), DME had occurred 3 to 18 months earlier, DME involved the fovea, and BCVA was ≤20/40 | PDR were excluded. No patients had undergone photocoagulation within the previous 12 months | IVB: 1.25 mg | 30-gauge needle | No | NR |
| Lanzagorta-Aresti et al. [14] | Moderate NPDR with diffuse macular edema, lasered with macular grid at 2 and 3 months preoperatively, central MT > 200 μm | Other associated ocular diseases capable of causing macular edema, patients who had had suffered complications during surgery or in the postoperative period | IVB: 1.25 mg | 3.5 mm from the limbus via a 30-gauge needle | No | Same |
| Cheema et al. [15] | (1) CSME; (2) mild, moderate, severe, or very severe NPDR or PDR; or (3) a combination of 1 and 2. Patients with previous focal or grid laser photocoagulation for CSME were eligible | Those with previous PRP for PDR | IVB: 1.25 mg | 3.0 to 3.5 mm from the limbus with a 27-gauge needle | Laser photocoagulation was performed according to ETDRS guidelines | Same |
| Chae et al. [16] | (1) Patients with NPDR, or patients with stable DR, who had completed PRP at least 3 months earlier; (2) patients with visually significant cataract with BCVA under 20/30; (3) patients with central subfield thickness (CST) that was <300 μm | Any kind of intravitreal drug injection within the previous 3 months; retinal laser treatment of diabetic ME within the previous 3 months, conditions (e.g., chronic ME, anatomical macular problem, and severe macular infarction) that the investigators believed are associated with a low probability of visual acuity restoration | IVR: 0.5 mg | 3 mm posterior to the limbus | Additive PRP due to vitreous hemorrhage | Four surgeons |
| Lin et al. [17] | NPDR without clinical DME | PDR was excluded, any kind of intravitreal drug injection preoperatively | IVR: 0.5 mg | NR | No | One |
| Lu et al. [18] | NPDR with clinical DME | | IVR: 0.5 mg | 3.5 mm posterior to the inferotemporal limbus | No | One |
| Cheng et al. [19] | NPDR without clinical DME | | IVR: 0.5 mg | | No | NR |
| Li [20] | NPDR with clinical DME | PDR, AMD, high myopia, intraocular surgery history | IVR: 0.5 mg | NR | No | One |
| Chen et al. [21] | Diffuse central macular edema of at least 250 mm, as demonstrated by OCT | Received laser photocoagulation less than 3 months before enrollment; concurrent PDR; IV injection of drugs within 6 months | IVB: 2.5 mg | 3.5 mm posterior to the inferotemporal limbus | | |
| Udaondo et al. [22] | Mild to moderate NPDR without clinical DME | Previous DME treated or not, any kind of complication during the surgery, other ocular pathology with macular involvement | IVR: 0.5 mg | NR | No | Same |
|
